You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

43 search results for: mechanism of disease

Chronic Spontaneous Urticaria (CSU): <b>Disease</b> Overview

Infographic

Chronic Spontaneous Urticaria (CSU): Disease Overview

5 min

Dermatology

Explore CSU: Uncover its clinical features, epidemiology, and its profound impact on patients' lives in this interactive tool.

Type 2 Inflammation and Its Role in Associated Dermatologic <b>Disease</b>s: A Two-Part Series

expert video

Type 2 Inflammation and Its Role in Associated Dermatologic Diseases: A Two-Part Series

30 min

Type 2 Inflammation

Join Dr. Raj Chovatiya as he reviews the pathophysiology and the role of type 2 inflammation in atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.

expert video

Type 2 Inflammation Contributes to the Signs and Symptoms of AD and PN

6 min

Dermatology

The impact of type 2 inflammation, neuroimmune axis dysfunction, and skin tissue on the signs and symptoms of atopic dermatitis and prurigo nodularis.

Cutaneous Manifestations in AD & PN: Role <b>of</b> Type 2 Inflammation

expert video

Cutaneous Manifestations in AD & PN: Role of Type 2 Inflammation

23 min

Dermatology

Type 2 inflammation in the distinct cutaneous manifestations of atopic dermatitis and prurigo nodularis – a clip from the ADVENT symposium at AAD 2023.

expert video

AD and PN: Diagnosis and Impact on Quality of Life

1 min

Dermatology

Approaches to diagnosis and the multidimensional burden of atopic dermatitis and prurigo nodularis – Highlight from the ADVENT symposium at AAD 2023.

Unique and Overlapping Roles <b>of</b> Type 2 Cytokines in AD and PN

expert video

Unique and Overlapping Roles of Type 2 Cytokines in AD and PN

1 min

Dermatology

Explore the unique and shared roles of type 2 cytokines in atopic dermatitis and prurigo nodularis – Highlight from the ADVENT symposium at AAD 2023.

expert video

An Overview of Prurigo Nodularis

38 min

Dermatology

Dr. Raj Chovatiya highlights the clinical features, epidemiology, burden, diagnosis, and pathophysiology of prurigo nodularis.

Unique Characteristics <b>of</b> Itch in AD, PN, and CSU – A Panel Discussion

expert video

Unique Characteristics of Itch in AD, PN, and CSU – A Panel Discussion

5 min

Dermatology

Dr. Kim and Dr. Elmariah discuss how unique characteristics of itch in AD, PN, and CSU impact patients.

ADVENT On Air | Common Drivers <b>of</b> Type 2 Inflammatory <b>Disease</b>s

audio

ADVENT On Air | Common Drivers of Type 2 Inflammatory Diseases

15 min

Type 2 Inflammation

Profs. Klaus Rabe and Stephan Weidinger discuss shared and unique features of type 2 inflammatory diseases and the benefits of multidisciplinary care

interactivity

Type 2 Inflammation and Neuronal Sensitization in AD and PN

5 min

Dermatology

Mechanisms of itch in normal skin and the effect of type 2 inflammation on neurons leading to chronic itch in atopic dermatitis and prurigo nodularis.

expert video

Fibrosis and Type 2 Inflammation in PN

2 min

Dermatology

The pathophysiology of fibrosis, a key component of skin manifestations in prurigo nodularis – Highlight from the ADVENT symposium at AAD 2023

expert video

Type 2 Inflammation and Cutaneous Manifestation in AD and PN

4 min

Dermatology

Pathophysiology of type 2 inflammation in the skin in two distinct, chronic pruritic dermatoses – atopic dermatitis and prurigo nodularis.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region